STOCKWATCH
·
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Quarterly ResultMay 6, 2026, 08:12 AM

Establishment Labs Q1 Revenue $59.9M, up 44.7%; Raises 2026 Guidance

AI Summary

Establishment Labs Holdings Inc. reported strong financial results for the first quarter ended March 31, 2026, with revenue increasing 44.7% year-over-year to $59.9 million. The company achieved its third consecutive quarter of positive adjusted EBITDA, reaching $1.2 million, and significantly narrowed its net loss. Based on this performance and accelerating momentum in both U.S. and OUS markets, Establishment Labs raised its full-year 2026 revenue guidance to a range of $266.5 million to $268.5 million and expects to be free cash flow positive in the second half of the year.

Key Highlights

  • Q1 2026 revenue was $59.9 million, a 44.7% increase from Q1 2025.
  • Raised 2026 revenue guidance to $266.5 million to $268.5 million.
  • Motiva sales in the United States reached $19.6 million, up 13.3% from Q4 2025.
  • Minimally invasive revenue for the quarter was $9.1 million.
  • Gross margin improved to 70.7% from 67.2% in the year-ago period.
  • Adjusted EBITDA was an income of $1.2 million, compared to a loss of $12.1 million in Q1 2025.
  • Net loss narrowed to $13.4 million from $20.7 million in Q1 2025.
  • Cash balance stood at $68.1 million as of March 31, 2026.
ESTA
Orthopedic, Prosthetic & Surgical Appliances & Supplies
ESTABLISHMENT LABS HOLDINGS INC.

Price Impact